Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study
Open Access
- 1 May 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 623-632
Abstract
Introduction: The increase in drugs available for severe uncontrolled asthma and the lifestyle of these patients make it necessary to implement self-administration programs of these therapies at home. Benralizumab, a monoclonal antibody targeting IL5R, was authorized in Spain for poorly controlled severe eosinophilic asthma. The possibility of administration at home was approved in March 2020 in Spain. The aim of the Auto-Benra study was to evaluate the usability and satisfaction of the benralizumab prefilled syringe and autoinjector and assessing the effectivity of these devices in uncontrolled severe eosinophilic asthma (SEA) in home-self administration. Methods: This is a retrospective, observational multicenter study uncontrolled SEA patients treated with benralizumab at least with 3 doses self-administered at home before April 30, 2021. Reliability and satisfaction with benralizumab at home were evaluated with subcutaneous administration assessment questionnaire (SQAAQ) and visual analogic scales (VAS). Effectiveness was evaluated in all patients with asthma control test (ACT), Mini Asthma Quality of Life Questionnaire (MiniAQLQ), annual exacerbation rate, oral corticosteroid treatment (OCS) and asthma-related hospitalizations and emergency visits. Results: Fifty-four patients across 9 hospitals in Spain were included. The mean SQAAQ score was 6.89 (± 0.16) points. Patients and their caregivers and doctors report excellent satisfaction by VAS, with no differences between benralizumab devices used (prefilled syringe and autoinjector). Severe exacerbation rate decreased by 65% (p = 0.0007) after benralizumab treatment. ACT score improved on average 6.27 ± 5.35 points (p < 0.0001) and the mean MiniAQLQ increased up to 1.58 ± 1.47 points (p < 0.0001). Twenty-four patients were OCS-dependent and at the end of study 14 patients get complete OCS withdrawal. Conclusion: AUTO-BENRA study supports the use of benralizumab at home given the excellent results of satisfaction and usability by patients and their caregivers.Keywords
This publication has 37 references indexed in Scilit:
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experienceMedical Devices: Evidence and Research, 2016
- Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic ReviewThe Patient - Patient-Centered Outcomes Research, 2014
- Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritisPatient Preference and Adherence, 2014
- Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — Results of the BetaPlus observational cohort studyJournal of the Neurological Sciences, 2011
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- Validation of the Spanish Version of the Asthma Control Test (ACT)Journal of Asthma, 2007
- Cuestionario de calidad de vida en pacientes con asma: la versión española del Asthma Quality of Life QuestionnaireArchivos de Bronconeumología, 1995